1. Home
  2. XXII vs BBLG Comparison

XXII vs BBLG Comparison

Compare XXII & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$1.49

Market Cap

1.5M

Sector

Health Care

ML Signal

HOLD

BBLG

Bone Biologics Corp

HOLD

Current Price

$0.48

Market Cap

1.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXII
BBLG
Founded
1998
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5M
1.2M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
XXII
BBLG
Price
$1.49
$0.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 129.3K
75.1K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.96
45.13
EPS
N/A
★ N/A
Revenue
$25,832,530.00
★ $1,070,000,000.00
Revenue This Year
$370.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.27
$0.43
52 Week High
$11.37
$2.89

Technical Indicators

Market Signals
Indicator
XXII
BBLG
Relative Strength Index (RSI) 32.53 37.23
Support Level $1.67 $0.43
Resistance Level $1.97 $0.59
Average True Range (ATR) 0.20 0.04
MACD 0.04 0.01
Stochastic Oscillator 9.58 62.38

Price Performance

Historical Comparison
XXII
BBLG

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The company manufactures and distributes the only combustible tobacco products containing minimally or non-addictive levels of nicotine. The Company has organized its business as a single reportable segment: tobacco, as it operates and derives all revenues from its tobacco operations and products.

About BBLG Bone Biologics Corp

Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.

Share on Social Networks: